The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Davis, J. M.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Davis, J. M.

Am J Psychiatry 1976; 133:208-214
Copyright © 1976 by American Psychiatric Association


REGULAR ARTICLES

Recent developments in the drug treatment of schizophrenia

JM Davis

The author reviews six topics relevant to the drug treatment of schizophrenia. The quantitative effectiveness of promazine is of interest with respect to the structural models of the phenothiazines and the dopamine theory of schizophrenia. The quantitative effectiveness of antipsychotic drugs is also important in evaluating new agents and therefore relevant to a discussion of two newly released neuroleptics, molindone and loxapine. The author's discussion of high- dose treatment of typical acute schizophrenics or treatment-resistant patients reviews the available data and calls attention to the fact that these areas of pharmacologic research have not received sufficient attention.


This article has been cited by other articles:


Home page
Schizophr BullHome page
T. Calton, M. Ferriter, N. Huband, and H. Spandler
A Systematic Review of the Soteria Paradigm for the Treatment of People Diagnosed With Schizophrenia
Schizophr Bull, January 1, 2008; 34(1): 181 - 192.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
G. Mercer, A. Finlayson, E. C. Johnstone, C. Murray, and D. G. C. Owens
A study of enhanced management in patients with treatment-resistant schizophrenia
J Psychopharmacol, January 1, 1997; 11(4): 349 - 356.
[Abstract] [PDF]


Home page
BMJHome page
E. C Johnstone and R. Sandler
Treatment resistance in schizophrenia
BMJ, February 10, 1996; 312(7027): 325 - 326.
[Full Text]


Home page
J PsychopharmacolHome page
D.G.C. Owens, P.E. Harrison-Read, and E. C. Johnstone
L-dopa helps positive but not negative features of neuroleptic-insensitive chronic schizophrenia
J Psychopharmacol, January 1, 1994; 8(4): 204 - 212.
[Abstract] [PDF]


Home page
ScienceHome page
P. Berger
Medical treatment of mental illness
Science, May 26, 1978; 200(4344): 974 - 981.
[Abstract] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 1976 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org